NCT06293833 2024-03-05
ZORALCS
University Hospital, Antwerp
Phase NA Unknown
Clinical Trials
91 trialsNCT05957510 2024-02-22
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT05829057 2024-02-13
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Zhejiang University
Phase 1 Unknown
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT05296603 2024-01-10
Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 2 Unknown
NCT06187740 2024-01-09
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
Fudan University
Phase 1 Unknown
NCT05991180 2023-12-27
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Unknown
NCT04985851 2023-12-01
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Phase NA Unknown
NCT05228496 2023-09-26
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05975944 2023-08-04
Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Unknown
NCT05901584 2023-06-18
Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC
Second Affiliated Hospital of Zunyi Medical University
Phase 2 Unknown
NCT05780307 2023-06-07
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Unknown
NCT03568097 2023-06-02
PAVE
Hellenic Cooperative Oncology Group
Phase 2 Unknown
NCT05873790 2023-05-24
Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study
The First Hospital of Jilin University
Unknown
NCT05826756 2023-04-28
PEER
LUNGevity Foundation
Unknown
NCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT05761977 2023-03-09
DRIVE
Hellenic Cooperative Oncology Group
Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT05668767 2022-12-30
Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Beijing Chest Hospital
Phase 2 Unknown
NCT04996771 2022-11-14
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05205421 2022-08-05
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
The First Affiliated Hospital of Bengbu Medical University
Phase 1 Unknown
NCT05027100 2022-07-01
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
Guangzhou University of Traditional Chinese Medicine
Phase NA Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT05320458 2022-04-11
Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer
Hasan Kalyoncu University
Phase NA Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT05191849 2022-01-14
Circulating EV Long RNA Profiles in SCLC
Fudan University
Phase NA Unknown
NCT04450043 2022-01-13
The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance
Massachusetts General Hospital
Phase NA Unknown
NCT04985201 2021-08-09
Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04698941 2021-07-29
Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04790955 2021-03-10
Effect of Combination Therapy on SCLC After Initial Treatment Failure
First Affiliated Hospital of Harbin Medical University
Unknown
NCT04782089 2021-03-04
Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer
Qilu Hospital of Shandong University
Phase NA Unknown
NCT04731909 2021-02-10
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Third Military Medical University
Phase NA Unknown
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT02171325 2021-02-03
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
Guangdong Association of Clinical Trials
Phase 2 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT03227016 2021-01-27
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Central European Society for Anticancer Drug Research
Phase 1 Unknown
NCT04696939 2021-01-06
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04675697 2020-12-19
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04672759 2020-12-17
A Real-world Study of Durvalumab for Lung Cancer in China
Peking Union Medical College Hospital
Unknown
NCT04663438 2020-12-11
Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
Peking Union Medical College Hospital
Unknown
NCT04659785 2020-12-09
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）
Tianjin Medical University Second Hospital
Phase 1/2 Unknown
NCT04647357 2020-11-30
A Trial of SHR-1316 Maintenance Therapy for Limited Stage Small Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT04453930 2020-07-01
A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT04314297 2020-03-19
Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03585998 2020-03-02
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Phase 2 Unknown
NCT03613597 2020-02-05
Etoposide Plus Lobaplatin Versus Etoposide Plus Cisplatin for Patients With Limited Small-cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT03613753 2020-02-05
Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer
Guizhou Medical University
Phase 2 Unknown
NCT04192682 2020-01-06
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
Changzhou Cancer Hospital of Soochow University
Phase 2/3 Unknown